New research suggests the timing of immunotherapy infusions may impact treatment outcomes for patients with early-stage triple-negative breast cancer (TNBC). A retrospective review of patients treated with neoadjuvant pembrolizumab indicates that those receiving infusions before 12:27 pm may experience higher rates of pathological complete response (pCR) compared to those treated later in the day. This finding aligns with emerging data from the American Society of Clinical Oncology regarding circadian-regulated immune activity in other solid tumors.
Why does infusion timing matter for immunotherapy?
The biological rationale behind timing immunotherapy involves the body’s circadian rhythm, which governs immune system function throughout the day. According to retrospective studies on metastatic melanoma, renal cell carcinoma, and non–small cell lung cancer (NSCLC), patients receiving infusions earlier in the day often show better progression-free and overall survival rates. Researchers hypothesize that the immune system’s varying activity levels throughout a 24-hour cycle may influence how effectively drugs like pembrolizumab interact with tumor cells.
A 2025 American Society of Clinical Oncology abstract highlighted a phase 3 trial in NSCLC patients, finding that morning infusions consistently yielded better clinical outcomes than afternoon treatments.
How was the TNBC study conducted?
The study utilized a retrospective chart review of patients diagnosed with early-stage TNBC who underwent neoadjuvant pembrolizumab therapy between July 2021 and July 2025. Investigators set the cutoff for “early” versus “late” infusion at 12:27 pm, matching methodologies used in prior melanoma research. Patients were categorized as “late” if they received all of their first three infusions after this time. The primary endpoint, pathological complete response (pCR), was defined specifically as ypT0/TisypN0.
What are the implications for clinical practice?
While the current sample size remains limited, the observed reduction in pCR rates for “late” infusions suggests that scheduling could eventually become a factor in oncology care. If larger datasets confirm these findings, clinical centers may need to prioritize morning slots for immunotherapy patients. This shift would mirror established protocols in other fields where timing is known to optimize drug efficacy. Further analysis is already underway to validate these initial observations and determine if they should influence standard treatment scheduling.
Comparing outcomes across cancer types
| Cancer Type | Timing Trend | Primary Source |
|---|---|---|
| Melanoma | Morning superiority | Prior literature |
| NSCLC | Morning superiority | 2025 ASCO Abstract |
| Early-stage TNBC | Potential pCR correlation | Recent Institutional Review |
Frequently Asked Questions
Does the time of day affect all cancer treatments?
Current research focuses specifically on immunotherapy. It is unclear if these findings apply to traditional cytotoxic chemotherapy or targeted therapies.
Should patients request morning appointments?
Not yet. The evidence is preliminary. Patients should discuss their treatment schedule with their oncology team, as clinical necessity and facility availability remain the primary drivers of scheduling.
What is a pathological complete response (pCR)?
A pCR, defined as ypT0/TisypN0, indicates that no invasive cancer cells are detectable in the breast tissue or lymph nodes following neoadjuvant therapy.
Stay informed about the latest developments in breast cancer research by tracking updates from the American Society of Clinical Oncology (ASCO) and major oncology journals.
Are you interested in the intersection of circadian biology and cancer care? Join the conversation in the comments below or subscribe to our newsletter to receive updates on emerging clinical trial data.
